SPINRAZA® is the commercial brand name of Nusinersen Sodium Injection, an antisense oligonucleotide therapeutic agent. It modulates the splicing of SMN2 pre‑mRNA, increases the production of functional survival motor neuron (SMN) protein, and alleviates motor neuron degeneration caused by spinal…
URECE® is the commercial brand name of Dotinurad Tablets, a selective urate reabsorption inhibitor developed by Fuji Yakuhin. It specifically inhibits renal URAT1 transporter, reduces uric acid reabsorption in proximal renal tubules, increases urinary uric acid excretion and lowers serum…
EYLEA® is the commercial brand name of Aflibercept Intravitreal Solution, developed by Bayer. It is a recombinant fusion protein that binds to vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), blocking their binding to corresponding receptors, inhibiting pathological…
ZEPZELCA® is the commercial brand name of Lurbinectedin for Injection, a synthetic marine-derived alkylating antitumor agent. It binds to the minor groove of tumor cell DNA, inhibits gene transcription and induces apoptosis of malignant cells, while also regulating the tumor…
Huatangning® is the commercial brand name of Dorzagliatin Tablets, a first-in-class oral glucokinase activator independently developed by Hua Medicine of China. It targets the glucose kinase sensor in pancreas, intestine and liver to regulate blood glucose in a glucose-dependent manner,…
Aidixi® is the domestic commercial brand name of Disitamab Vedotin For Injection, a domestically developed HER2-targeted antibody-drug conjugate (ADC) independently researched and developed by RemeGen. It consists of a humanized anti-HER2 monoclonal antibody conjugated with MMAE via a cleavable linker.…
Trodelvy® is the international commercial brand name of Sacituzumab Govitecan for Injection, marketed domestically under the Chinese brand name Tuodavi® and developed by Gilead Sciences. It is a Trop-2 targeted antibody-drug conjugate (ADC). The antibody specifically binds to Trop-2 on…
SULANDA® is the commercial brand name of Surufatinib Capsules, an oral small-molecule multi-target tyrosine kinase inhibitor independently developed by HUTCHMED. It inhibits VEGFR, FGFR and CSF-1R simultaneously, exerting dual anti-angiogenic and immune-modulating anti-tumor effects. Main IndicationsMonotherapy for unresectable locally advanced…
Carteyva® is the international commercial brand name of Relmacabtagene Autoleucel Injection, domestically marketed under the Chinese brand name Beinuoda®. It is an autologous CD19-targeted CAR-T cell immunotherapy developed by JW Therapeutics. Patient-derived T cells are genetically modified ex vivo to…
Conmana® is the commercial brand name of Icotinib Hydrochloride Tablets, an orally administered epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) independently developed in China. It selectively inhibits EGFR tyrosine kinase activity, blocks downstream signal transduction, and suppresses proliferation and…